Fulvestrant in Treating Patients With Recurrent, Persistent, or Metastatic Endometrial Cancer
Status:
Unknown status
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase II trial is studying fulvestrant to see how well it works in treating patients
with recurrent, persistent, or metastatic endometrial cancer. Estrogen can stimulate the
growth of cancer cells. Hormone therapy using fulvestrant may fight cancer by blocking the
uptake of estrogen by the tumor cells.